Total Payments
$3,239
2024 Payments
$67.46
Companies
23
Transactions
159
Medicare Patients
1,605
Medicare Billing
$150,681
Payment Breakdown by Category
Food & Beverage$2,681 (82.8%)
Travel$458.03 (14.1%)
Education$99.95 (3.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,681 | 156 | 82.8% |
| Travel and Lodging | $458.03 | 2 | 14.1% |
| Education | $99.95 | 1 | 3.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,156 | 64 | $0 (2023) |
| Covidien LP | $493.00 | 4 | $0 (2018) |
| Janssen Biotech, Inc. | $232.86 | 11 | $0 (2022) |
| Boston Scientific Corporation | $219.03 | 5 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $172.45 | 10 | $0 (2017) |
| Supernus Pharmaceuticals, Inc. | $145.28 | 6 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $137.96 | 12 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $128.39 | 8 | $0 (2022) |
| UCB, Inc. | $115.05 | 8 | $0 (2019) |
| Daiichi Sankyo Inc. | $87.04 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67.46 | 1 | Boston Scientific Corporation ($67.46) |
| 2023 | $132.84 | 7 | ABBVIE INC. ($79.95) |
| 2022 | $494.77 | 23 | ABBVIE INC. ($362.74) |
| 2021 | $575.25 | 26 | AbbVie Inc. ($395.04) |
| 2020 | $177.88 | 10 | AbbVie Inc. ($36.39) |
| 2019 | $175.22 | 11 | AbbVie, Inc. ($69.87) |
| 2018 | $1,082 | 49 | Covidien LP ($481.10) |
| 2017 | $533.31 | 32 | Valeant Pharmaceuticals North America LLC ($172.45) |
All Payment Transactions
159 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/18/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $67.46 | General |
| Category: General - Biliary Devices_ENDO | ||||||
| 07/10/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $15.58 | General |
| Category: Neuroscience | ||||||
| 03/31/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $19.35 | General |
| 02/27/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: IMMUNOLOGY | ||||||
| 02/22/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/09/2023 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: IMMUNOLOGY | ||||||
| 01/31/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: IMMUNOLOGY | ||||||
| 01/10/2023 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/21/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2022 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $3.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/21/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/26/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.80 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2022 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $8.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/21/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: VIROLOGY | ||||||
| 07/19/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Gastroenterology | ||||||
| 07/12/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: IMMUNOLOGY | ||||||
| 06/10/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: IMMUNOLOGY | ||||||
| 06/03/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2022 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $23.60 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/28/2022 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: VIROLOGY | ||||||
| 04/18/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: IMMUNOLOGY | ||||||
| 04/11/2022 | ABBVIE INC. | RINVOQ (Biological), HUMIRA | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: IMMUNOLOGY | ||||||
| 04/05/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Education | In-kind items and services | $99.95 | General |
| Category: Immunology | ||||||
| 03/31/2022 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 33 | 33 | $3,825 | $966.56 |
| 2022 | 13 | 550 | 592 | $191,826 | $55,454 |
| 2021 | 13 | 528 | 568 | $175,209 | $51,752 |
| 2020 | 12 | 494 | 586 | $139,345 | $42,508 |
Total Patients
1,605
Total Services
1,779
Medicare Billing
$150,681
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 33 | $3,825 | $966.56 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 133 | 157 | $18,085 | $8,958 | 49.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 42 | 43 | $32,164 | $7,780 | 24.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 41 | 41 | $22,386 | $6,928 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $10,675 | $6,909 | 64.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 44 | 44 | $27,852 | $5,587 | 20.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 73 | 73 | $33,580 | $5,399 | 16.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 29 | 29 | $15,834 | $3,655 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 33 | $4,725 | $2,636 | 55.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 14 | 14 | $7,644 | $2,305 | 30.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 33 | $2,475 | $1,698 | 68.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 22 | 22 | $9,504 | $1,678 | 17.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 13 | 13 | $1,885 | $1,080 | 57.3% |
| 43450 | Dilation of esophagus | Facility | 2022 | 29 | 29 | $5,017 | $840.34 | 16.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 130 | 165 | $19,005 | $9,286 | 48.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 61 | 61 | $10,645 | $6,262 | 58.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 36 | 36 | $19,656 | $6,199 | 31.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 71 | 71 | $32,660 | $5,772 | 17.7% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 29 | 29 | $21,692 | $5,379 | 24.8% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 34 | 34 | $21,522 | $4,725 | 22.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 47 | $6,650 | $3,505 | 52.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 20 | 20 | $10,920 | $3,234 | 29.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 29 | 29 | $4,205 | $2,192 | 52.1% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 16 | 17 | $9,282 | $1,851 | 19.9% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 17 | 18 | $7,776 | $1,478 | 19.0% |
About Dr. Mark Jackson, MD
Dr. Mark Jackson, MD is a Gastroenterology healthcare provider based in Knoxville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699745273.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Jackson, MD has received a total of $3,239 in payments from pharmaceutical and medical device companies, with $67.46 received in 2024. These payments were reported across 159 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($2,681).
As a Medicare-enrolled provider, Jackson has provided services to 1,605 Medicare beneficiaries, totaling 1,779 services with total Medicare billing of $150,681. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Knoxville, TN
- Active Since 01/25/2006
- Last Updated 02/03/2012
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1699745273
Products in Payments
- HUMIRA (Biological) $396.06
- RINVOQ (Biological) $265.16
- Humira (Biological) $248.06
- Barrx (Device) $209.19
- STELARA (Biological) $199.11
- LINZESS (Drug) $178.06
- QELBREE (Drug) $145.28
- SPYGLASS (Device) $123.39
- Cimzia (Drug) $115.05
- XIFAXAN (Drug) $114.23
- Amitiza (Drug) $95.40
- INJECTAFER (Drug) $87.04
- UCERIS (Drug) $85.34
- MOVIPREP (Drug) $58.46
- ENTYVIO (Biological) $56.64
- MAVYRET (Drug) $50.20
- XIFAXANIBSD (Drug) $42.81
- CLENPIQ (Drug) $39.60
- Creon (Drug) $34.29
- REMICADE (Biological) $33.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Knoxville
Dr. Carlos Rollhauser, Md, MD
Gastroenterology — Payments: $213,612
Gastroenterology $213,612
Raj Narayani, Md, MD
Gastroenterology — Payments: $181,238
Gastroenterology $181,238
Thomas Young, Md, MD
Gastroenterology — Payments: $33,354
Gastroenterology $33,354
Meade Edmunds, Md, MD
Gastroenterology — Payments: $20,947
Gastroenterology $20,947
Charles O'connor, Md, MD
Gastroenterology — Payments: $19,665
Gastroenterology $19,665
Robert Pollack, Md, MD
Gastroenterology — Payments: $16,442
Gastroenterology $16,442